Saturday 17 October 2026 Export NXGL’s income statement to Excel — free account

NexGel, Inc.

NXGL Healthcare Medical Instruments & Supplies

NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024. In the quarter to June 2026, revenue grew 27.8%, EPS fell 344.4%, free cash flow fell 432.3% and total debt rose 353.8%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five.

5.59 0.41 +7.92%

Follow NXGL

Alert me

Market cap: $15.9M
P/E: 0.0×
Fwd P/E: −4.7×
Dividend yield: —
F-score: 5/9
Altman Z: 24.63
Beneish M: −3.41
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	—	—	—	—	1	4	—	—	—	—

Insider Ownership 95.34%

Capital & Financial Ratios $m

Market Cap 15.92

Revenue 12.07

Net Income (6.05)

Free Cash Flow (3.34)

Net Debt 1.99

Current Ratio 0.43

Debt/Equity 0.68

P/E ratio 0.00

Fwd P/E (4.67)

P/S ratio 4.18

P/B ratio 9.22

Past 5Y EPS Growth —

This Y EPS Growth (147.37%)

Next Y EPS Growth 76.60%

Next Y revenue growth 38.25%

Next 5Y EPS Growth 49.14%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.90%

10-year low 10-year high

P/B against its own 10 years 2.73%

10-year low 10-year high

EV/Sales against its own 10 years 1.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	2	1	2
Receivables	1	1	1	1
Inventory	1	2	2	2
Other	—	—	—	—
	5	5	4	6

	2023	2024	2025	Q'26
Payables	1	1	1	4
ST’ Debt	—	—	—	—
Other	1	0	—	9
	3	2	3	14

Compound Annual Growth %

	10y	5y	3y
Sales	—	76.12%	77.33%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	133.15%	(13.80%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	4	—	—	—
’25	3	3	3	3	11
’24	1	1	3	3	9
’23	1	1	1	1	4
’22	0	1	1	1	2
’21	0	0	0	1	2
’20	0	0	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	0	0	(1)	0	(1)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(3)
’22	(1)	(1)	(1)	(1)	(3)
’21	0	(1)	(1)	(1)	(3)
’20	(1)	0	0	0	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	0	0	(1)	0	(1)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(4)
’22	(1)	(1)	(1)	(1)	(3)
’21	(1)	(1)	(1)	(1)	(3)
’20	(1)	0	0	(1)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.11)	(0.40)	—	—	—
’25	(0.09)	(0.09)	(0.08)	(0.12)	(0.38)
’24	(0.14)	(0.14)	(0.11)	(0.11)	(0.50)
’23	(0.15)	(0.12)	(0.10)	(0.19)	(0.56)
’22	(0.33)	(0.19)	(0.22)	(0.11)	(0.85)
’21	(0.24)	(0.28)	(0.38)	(0.54)	(1.45)
’20	(0.01)	(0.01)	(0.01)	(0.98)	(1.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	51.00	21.80	23.60	36.80	29.00	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	93.20	72.40	61.00	102.00	90.50
People
People	Employees	—	—	—	—	—	10	12	19	19	19
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.16	0.17	0.22	0.46	0.60
Income, $m
Income, $m	Revenue	—	—	2	1	1	2	2	4	9	11
	Gross margin, %	—	—	21.92	(22.45)	(43.18)	0.52	12.50	9.15	31.63	39.48
	EBT	—	—	(2)	(2)	(2)	(4)	(5)	(3)	(3)	(3)
	EBT margin, %	—	—	(85.31)	(268.20)	(335.91)	(277.89)	(231.74)	(77.97)	(39.86)	(25.33)
	Net income	—	0	(2)	(2)	(2)	(4)	(5)	(3)	(3)	(3)
	Depreciation	—	—	0	0	0	2	1	0	1	1
Per share, $
Per share, $	Revenue	—	—	0.44	0.05	0.30	0.52	0.37	0.72	1.33	1.45
	Earnings	—	—	(0.38)	(0.14)	(1.00)	(1.45)	(0.85)	(0.56)	(0.50)	(0.38)
	Cash flow	—	—	(0.31)	(0.13)	(0.80)	(0.92)	(0.54)	(0.57)	(0.59)	(0.17)
	Capex	—	—	0.00	0.00	(0.14)	(0.09)	(0.02)	(0.12)	(0.07)	(0.01)
	Free cash flow	—	—	(0.31)	(0.13)	(0.94)	(1.01)	(0.55)	(0.69)	(0.66)	(0.18)
	Book value	—	—	0.06	0.03	0.03	4.06	1.37	0.91	0.93	0.62
	Shares, m	—	—	5	14	2	3	6	6	7	8
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	187.25	187.25	187.25	100.29	73.50	62.42	66.86	22.14
	P/B	—	—	433.31	433.31	433.31	12.87	19.71	49.41	95.54	51.71
	EV/Sales	—	—	186.38	186.38	186.38	91.86	70.41	61.89	66.76	22.12
	EV/FCF	—	—	(82.54)	(82.54)	(82.54)	(47.15)	(48.60)	(64.36)	(134.58)	(174.49)
Cash, $m
Cash, $m	Operating cash flow	—	—	(2)	(2)	(2)	(3)	(3)	(3)	(4)	(1)
	Capex	—	—	—	—	0	0	0	(1)	0	0
	Free cash flow	—	—	(2)	(2)	(2)	(3)	(3)	(4)	(4)	(1)
Balance, $m
Balance, $m	Working capital	—	—	0	0	(1)	11	7	3	3	1
	Total debt	—	—	—	1	0	0	0	1	1	1
	Net debt	—	—	—	1	0	(13)	(6)	(2)	(1)	0
	Shareholders’ equity	—	—	0	0	0	12	8	5	6	5
Returns, %
Returns, %	ROA	—	—	(510.96)	(146.29)	(109.19)	(44.80)	(34.72)	(31.09)	(31.34)	(27.98)
	ROIC	—	—	0.00	0.00	(478.81)	0.00	(161.46)	(72.95)	(42.98)	(45.90)
	ROE	—	—	(571.26)	(581.85)	(1,003.99)	(70.91)	(48.13)	(49.32)	(58.35)	(54.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HBIO Harvard Bioscience, Inc.	$37.8M	— (loss-making)	— (loss-making)	+11.13% (above 0%: growing)	n/m	−123.43% (below 0%: shrinking)	55.57%	(4.30%)	Compare
MLSS Milestone Scientific, Inc.	$29.6M	— (loss-making)	— (loss-making)	+22.27% (above 0%: growing)	n/m	+66.68% (above 0%: growing)	67.24%	(37.37%)	Compare
RVP Retractable Technologies, Inc.	$17.6M	— (loss-making)	11.1×	−31.07% (below 0%: shrinking)	n/m	+56.67% (above 0%: growing)	2.65%	(71.46%)	Compare
BNGO Bionano Genomics, Inc.	$16.1M	— (loss-making)	— (loss-making)	+21.36% (above 0%: growing)	n/m	−33.93% (below 0%: shrinking)	52.80%	(88.34%)	Compare
NXGL NexGel, Inc.	$15.9M	— (loss-making)	— (loss-making)	+27.81% (above 0%: growing)	n/m	−432.32% (below 0%: shrinking)	30.09%	(67.96%)
FEMY Femasys Inc.	$14.5M	— (loss-making)	— (loss-making)	−18.93% (below 0%: shrinking)	n/m	+11.29% (above 0%: growing)	57.08%	(1,526.79%)	Compare
CUPR Cuprina Holdings (Cayman) Limited	$11.5M	—	—	—	—	—	—	—	Compare
RGNT Regentis Biomaterials Ltd.	$10.9M	—	—	—	—	−132.79% (below 0%: shrinking)	—	—	Compare
LUCY Innovative Eyewear, Inc.	$7.3M	— (loss-making)	—	+74.46% (above 0%: growing)	n/m	+9.61% (above 0%: growing)	24.00%	(168.73%)	Compare
Median of peers	$15.3M	—	—	+16.25%	—	+9.61%	54.18%	(79.90%)

All 55 Medical Instruments & Supplies stocks →

NexGel, Inc. (NXGL) key facts

Concern: NexGel, Inc. reported a net loss of $2.9 million, or a loss of $0.38 per share, for fiscal 2025.
Strength: NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024.
NexGel, Inc. (NXGL) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NXGL traded at $5.59, a market capitalization of $15.9 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.2× sales.
Return on equity was −54.7% and debt-to-equity 0.68.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 24.63 (safe zone) for fiscal 2025.